Following intra‐CSF treatment of patients with LM and breast cancer, survival has typically ranged from 2.9‐5.4 months,4, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 and up to 13.6 months in HER2+ patients treated with intra‐CSF trastuzumab.25 This evidence concerns the gene ERBB2 and breast carcinoma.